{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:06:27Z","timestamp":1792559187419,"version":"4.5.0"},"reference-count":59,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,7,31]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Introduction<\/jats:title>\n                  <jats:p>There is an unmet need for new treatments for idiopathic pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study in patients with IPF. This study design describes the subsequent pivotal phase III study of BI 1015550 in patients with IPF (FIBRONEER-IPF).<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this placebo-controlled, double-blind, phase III trial, patients are being randomised in a 1:1:1 ratio to receive 9 mg or 18 mg of BI 1015550 or placebo two times per day over at least 52 weeks, stratified by use of background antifibrotics (nintedanib\/pirfenidone vs neither). The primary endpoint is the absolute change in FVC at week 52. The key secondary endpoint is a composite of time to first acute IPF exacerbation, hospitalisation due to respiratory cause or death over the duration of the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial is being carried out in compliance with the ethical principles of the Declaration of Helsinki, in accordance with the International Council on Harmonisation Guideline for Good Clinical Practice and other local ethics committees. The results of the study will be disseminated at scientific congresses and in peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05321069\">NCT05321069<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001563","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T08:10:19Z","timestamp":1692432619000},"page":"e001563","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct05321069","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05321069","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05321082","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-9966","authenticated-orcid":false,"given":"Luca","family":"Richeldi","sequence":"first","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan"},{"name":"Respiratory Medicine and Clinical Research Centre, Meisei Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Louis Pradel, Centre Coordonnateur National de r\u00e9f\u00e9rence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754, INRAE, Universit\u00e9 Claude Bernard Lyon 1, Member of ERN-LUNG, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Centre for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg, German Center for Lung Research, Heidelberg, Germany"},{"name":"Department of Pneumology, RKH Clinic Ludwigsburg, Ludwigsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Critical Care and Sleep Medicine, USC Keck School of Medicine, Los Angeles, California, USA"},{"name":"Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cornell University, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M","family":"Oldham","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-6290","authenticated-orcid":false,"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Gordat","sequence":"additional","affiliation":[{"name":"Clinical Development & Operation Department, Boehringer Ingelheim, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[{"name":"TA Inflammation Med, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F","family":"Zoz","sequence":"additional","affiliation":[{"name":"Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"2025083110170725000_10.1.e001563.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025083110170725000_10.1.e001563.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807508"},{"key":"2025083110170725000_10.1.e001563.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025083110170725000_10.1.e001563.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025083110170725000_10.1.e001563.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025083110170725000_10.1.e001563.6","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083110170725000_10.1.e001563.7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.chest.2021.10.021","article-title":"Pulmonary rehabilitation in idiopathic pulmonary fibrosis and COPD: a propensity-matched real-world study","volume":"161","author":"Nolan","year":"2022","journal-title":"Chest"},{"key":"2025083110170725000_10.1.e001563.8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2213-2600(18)30502-2","article-title":"Lung transplantation for idiopathic pulmonary fibrosis","volume":"7","author":"George","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025083110170725000_10.1.e001563.9","unstructured":"Boehringer Ingelheim International GmbH . OFEV\u00ae (nintedanib) capsules, for oral use. 2022. Available: https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf [Accessed 24 Nov 2022]."},{"key":"2025083110170725000_10.1.e001563.10","unstructured":"US Food and Drug Administration . OFEV\u00ae (nintedanib): prescribing information. 2020. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205832s014lbl.pdf [Accessed 17 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.11","unstructured":"European Medicines Agency . OFEV\u00ae (nintedanib): summary of product characteristics. 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf [Accessed 12 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.12","unstructured":"US Food and Drug Administration . ESBRIET\u00ae (pirfenidone): prescribing information. 2019. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022535s012,208780s002lbl.pdf [Accessed 12 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.13","unstructured":"Genentech . ESBRIET\u00ae (pirfenidone) capsules and film-coated tablets, for oral use. 2022. Available: https:\/\/www.gene.com\/download\/pdf\/esbriet_prescribing.pdf [Accessed 17 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.14","unstructured":"European Medicines Agency . Esbriet\u00ae (pirfenidone): summary of product characteristics. 2022. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002154\/WC500103049.pdf [Accessed 17 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230"},{"key":"2025083110170725000_10.1.e001563.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"key":"2025083110170725000_10.1.e001563.17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000496735","article-title":"A 2-year observational study in patients suffering from idiopathic pulmonary fibrosis and treated with Pirfenidone: a French ancillary study of PASSPORT","volume":"98","author":"Jouneau","year":"2019","journal-title":"Respiration"},{"key":"2025083110170725000_10.1.e001563.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2025083110170725000_10.1.e001563.19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry","volume":"56","author":"Behr","year":"2020","journal-title":"Eur Respir J"},{"key":"2025083110170725000_10.1.e001563.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000782","article-title":"Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis","volume":"8","author":"Wright","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2025083110170725000_10.1.e001563.21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2025083110170725000_10.1.e001563.22","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1053"},{"key":"2025083110170725000_10.1.e001563.23","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2025083110170725000_10.1.e001563.24","doi-asserted-by":"crossref","first-page":"173508","DOI":"10.1016\/j.ejphar.2020.173508","article-title":"A novel phosphodiesterase 4 inhibitor, Aa6216, reduces macrophage activity and fibrosis in the lung","volume":"885","author":"Matsuhira","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025083110170725000_10.1.e001563.25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025083110170725000_10.1.e001563.26","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025083110170725000_10.1.e001563.27","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13753","article-title":"Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury","volume":"6","author":"Sisson","year":"2018","journal-title":"Physiol Rep"},{"key":"2025083110170725000_10.1.e001563.28","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22529"},{"key":"2025083110170725000_10.1.e001563.29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","article-title":"The discovery of Roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Cazzola","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"2025083110170725000_10.1.e001563.30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025083110170725000_10.1.e001563.31","doi-asserted-by":"publisher","DOI":"10.1080\/01926230500385549"},{"key":"2025083110170725000_10.1.e001563.32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215506"},{"key":"2025083110170725000_10.1.e001563.33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025083110170725000_10.1.e001563.34","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00240-2022","article-title":"Phase I studies of BI 1015550, a preferential Pde4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis","volume":"8","author":"Maher","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025083110170725000_10.1.e001563.35","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025083110170725000_10.1.e001563.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2025083110170725000_10.1.e001563.37","doi-asserted-by":"crossref","first-page":"00145","DOI":"10.1183\/23120541.00145-2020","article-title":"The living with pulmonary fibrosis questionnaire in progressive fibrosing interstitial lung disease","volume":"7","author":"Swigris","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025083110170725000_10.1.e001563.38","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","article-title":"The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Cazzola","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"2025083110170725000_10.1.e001563.39","unstructured":"European Medicines Agency . Otezla\u00ae (apremilast): summary of product characteristics. 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf [Accessed 2 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.40","unstructured":"US Food and Drug Administration . OTEZLA\u00ae (apremilast): prescribing information. 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205437s011lbl.pdf [Accessed 23 Feb 2022]."},{"key":"2025083110170725000_10.1.e001563.41","unstructured":"US Food and Drug Administration . DALIRESP\u00ae (roflumilast): prescribing information. 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022522s009lbl.pdf [Accessed 28 Jan 2022]."},{"key":"2025083110170725000_10.1.e001563.42","unstructured":"European Medicines Agency . Daxas\u00ae (roflumilast): summary of product characteristics. 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/daxas-epar-product-information_en.pdf [Accessed 2 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.43","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"2025083110170725000_10.1.e001563.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir Res"},{"key":"2025083110170725000_10.1.e001563.45","doi-asserted-by":"crossref","first-page":"L600","DOI":"10.1152\/ajplung.00310.2021","article-title":"From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump","volume":"321","author":"Selman","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2025083110170725000_10.1.e001563.46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1164\/rccm.201903-0592PP","article-title":"Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies","volume":"200","author":"Kaner","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110170725000_10.1.e001563.47","doi-asserted-by":"crossref","unstructured":"Richeldi L , Azuma A , Cottin V , et al . Additive effect of BI 1015550 and nintedanib in patients with IPF (OA1396). ERS International Congress 2022 abstracts; Barcelona, Spain: European Respiratory Society, September 4, 2022 doi:10.1183\/13993003.congress-2022.4606","DOI":"10.1183\/13993003.congress-2022.4606"},{"key":"2025083110170725000_10.1.e001563.48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14728222.2019.1552262","article-title":"New Therapeutics based on emerging concepts in pulmonary fibrosis","volume":"23","author":"Sontake","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"2025083110170725000_10.1.e001563.49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797292","article-title":"Idiopathic pulmonary fibrosis: an update on pathogenesis","volume":"12","author":"Mei","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025083110170725000_10.1.e001563.50","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-05004-8","article-title":"Managing clinical trials during COVID-19: experience from a clinical research facility","volume":"22","author":"Shiely","year":"2021","journal-title":"Trials"},{"key":"2025083110170725000_10.1.e001563.51","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110170725000_10.1.e001563.52","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2025083110170725000_10.1.e001563.53","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000091"},{"key":"2025083110170725000_10.1.e001563.54","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0075-2018","article-title":"Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases","volume":"27","author":"Swigris","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2025083110170725000_10.1.e001563.55","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00681-2021","article-title":"Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures","volume":"8","author":"Wijsenbeek","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025083110170725000_10.1.e001563.56","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025083110170725000_10.1.e001563.57","unstructured":"US Food and Drug Administration . Roflumilast: tertiary pharmacology review. 2009. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000PharmR.pdf [Accessed 2 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.58","unstructured":"European Medicines Agency . Summary of risk management plan for Otezla\u00ae (Apremilast). 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/otezla-epar-risk-management-plan-summary_en.pdf [Accessed 2 Aug 2022]."},{"key":"2025083110170725000_10.1.e001563.59","unstructured":"US Food and Drug Administration . Apremilast: tertiary pharmacology review. 2014. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205437Orig1s000PharmR.pdf [Accessed 2 Aug 2022]."}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:17:21Z","timestamp":1756660641000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,18]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjresp-2022-001563"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001563","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}